Managing the clinical consequences of psychiatric illness and antipsychotic treatment: A discussion of obesity, diabetes, and hyperprolactinemia

Journal of the American Psychiatric Nurses Association

Volumn 10, Issue 3 SUPPL., 2004, Pages

  Vreeland, Betty ^a   Kim, Edward ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Hyperprolactinemia; Obesity; Psychotropic associated weight gain; Type 2 diabetes

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; INSULIN; LAMOTRIGINE; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; ZIPRASIDONE;

AMENORRHEA; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES CONTROL; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOCRINE BREAST DISEASE; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEALTH HAZARD; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LACTATION DISORDER; LIBIDO DISORDER; LIFE EXPECTANCY; MALE; MEDICAL ASSESSMENT; MENSTRUATION DISORDER; MENTAL DISEASE; MENTAL HEALTH SERVICE; METABOLIC BONE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING; OBESITY; ORGASM DISORDER; OSTEOPOROSIS; PSYCHIATRIC DIAGNOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT PLANNING;

EID: 4344606190     PISSN: 10783903     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078390304265287     Document Type: Article

References (47)

1. American Diabetes Association. (2002). Standards of medical care for patients with diabetes mellitus. Diabetes Care, 25, 33-49.
2. American Diabetes Association. (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26(Suppl. 1), S5-S20.
3. Brown, S., Birtwistle, J., Roe, L., & Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697-701.
4. Cassidy, F., Ahearn, E., & Carroll, B. J. (1999). Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. American Journal of Psychiatry, 156, 1417-1420.
5. Centers for Disease Control and Prevention. (2003). Overweight and obesity. Retrieved December 12, 2003, from http://www.cdc.gov/nccdphp/dnpa/obesity/
6. Cradock-O'Leary J., Young, A. S., Yano, E. M., Wang, M., & Lee, M. L. (2002). Use of general medical services by VA patients with psychiatric disorders. Psychiatric Services, 53, 874-878.
7. Crawford, A. M., Beasley, C. M., & Tollefson, G. D. (1997). The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26, 41-54.
8. Dembling, B. P., Chen, D. T., & Vachon, L. (1999). Life expectancy and causes of death in a population treated for serious mental illness. Psychiatric Services, 50, 1036-1042.
9. Dickey, B., Normand, S. L., Weiss, R. D., Drake, R. E., & Azeni, H. (2002). Medical morbidity, mental illness, and substance use disorders. Psychiatry Services, 53, 861-867.
10. Dixon, L., Weiden, P., Delahanty J., Goldberg, R. J., Postrado, L., Lucksted, A., et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin., 26, 903-912.
11. Elmslie, J. L., Mann, J. I., Silverstone, J. T., Williams, S. M., & Romans, S. E. (2001). Determinants of overweight and obesity in patients with bipolar disorder. Journal of Clinical Psychiatry, 62, 486-491.
12. Elmslie, J. L., Silverstone, J. T., Mann, J. I., Williams, S. M., & Romans, S. E. (2000). Prevalence of overweight and obesity in bipolar patients. Journal of Clinical Psychiatry, 61, 179-184.
13. Fagiolini, A., Frank, E., Houck, P. R., Mallinger, A. G., Swartz, H. A., Buysse, D. J., et al. (2002). Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. Journal of Clinical Psychiatry, 63, 528-533.
14. Fagiolini, A., Kupfer, D. J., Houck, P. R., Novick, D. M., & Frank, E. (2003). Obesity as a correlate of outcome in patients with bipolar I disorder. American Journal of Psychiatry, 160, 112-117.
15. Food and Drug Administration's proposed diabetes warning. (2003). Psychiatric News, 38, 26.
16. Genuth, S., Alberti, K. G., Bennett, P., Buse, J., Defronzo, R., Kahn, R., et al. (2003). Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 26, 3160-3167.
17. Glassman, A. H., Covey, L. S., Dalack, G. W., Stetner, F., Rivelli, S. K., Fleiss, J., et al. (1993). Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology and Therapeutics, 54, 670-679.
18. Goodnick, P. J., Rodriguez, L., & Santana, O. (2002). Antipsychotics: Impact on prolactin levels. Expert Opinion on Pharmacotherapy, 3, 1381-1391.
19. Greenberg, I., Chan, S., & Blackburn, G. L. (1999). Nonpharmacologic and pharmacologic management of weight gain. Journal of Clinical Psychiatry, 60(Suppl. 21), 31-36.
20. Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986). Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993-997.
21. Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996). Medical comorbidity in schizophrenia. Schizophrenia Bulletin, 22, 413-430.
22. Kaplan, H., Sadock, B. J., & Grebb, J. A. (1994). Synopsis of psychiatry: Behavorial sciences, clinical psychiatry. Baltimore: Williams & Wilkins.
23. Kapur, S., Langlois, X., Vinken, P., Megens, A. A., de Coster, R., & Andrews, J. S. (2002). The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. The Journal of Pharmacology and Experimental Therapeutics, 302, 1129-1134.
24. Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514-520.
25. Keskiner, A., el Toumi, A., & Bousquet, T. (1973). Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics, 14, 176-181.
26. Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003). Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology, 28(Suppl. 2),55-68.
27. Koranyi, E. K. (1977). Fatalities in 2,070 psychiatric outpatients. Archives of General Psychiatry, 34, 1137-1142.
28. Koranyi, E. K. (1979). Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Archives of General Psychiatry, 36, 414-419.
29. Lilliker, S. L. (1980). Prevalence of diabetes in a manic-depressive population. Comprehensive Psychiatry, 21, 270-275.
30. Linkowski, P., Van Cauter, E., L'Hermite-Baleriaux, M., Kerkhofs, M., Hubain, P., L'Hermite, M., et al. (1989). The 24-hour profile of plasma prolactin in men with major endogenous depressive illness. Archives General Psychiatry, 46, 813-819.
31. Littrell, K. H., Hilligoss, N. M., Kirshner, C. D., Petty, R. G., & Johnson, C. G. (2003). The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship, 35, 237-241.
32. Marder, S. R., & Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
33. McCloughen, A. (2003). The association between schizophrenia and cigarette smoking: A review of the literature and implications for mental health nursing practice. International Journal of Mental Health Nursing, 12, 119-129.
34. McKee, H. A., D'Arcy, P. F., & Wilson, P. J. (1986). Diabetes and schizophrenia - A preliminary study. Journal of Clinical and Hospital Pharmacy, 11, 297-299.
35. Menza, M., Vreeland B., Minsky S., Gara, M., Rigassio Radler D., Sakowitz, M. (In press). Managing atypical antipsychotic-associated weight gain: A prospective, 12-Month, multi-modal weight control program. Journal of Clinical Psychiatry.
36. Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. L. (1996). Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68-73.
37. National Heart, Lung, and Blood Institute. (1998). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Retrieved December 12, 2003, from http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf
38. Nguyen, C. T., Ortiz, T., Franklin, D., & Maguire, G. A. (2001, May). Nutritional education in minimizing weight gain associated with antipsychotic therapy. Paper presented at the annual meeting of the American Psychiatric Association, New Orleans, LA.
39. Regenold, W. T., Thapar, R. K., Marano, C., Gavirneni, S., & Kondapavuluru, P. V. (2003). Corrigendum to "Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use." Journal of Affective Disorders, 73, 301-302.
40. Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561-566.
41. Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications (2nd ed.). New York: Cambridge University Press.
42. Vanable, P. A., Carey, M. P., Carey K. B., & Maisto, S. A. (2003). Smoking among psychiatric outpatients: Relationship to substance use, diagnosis, and illness severity. Psychology of Addictive Behaviors, 17, 259-265.
43. Vieweg, V., Levenson, J., Pandurangi, A., & Silverman, J. (1995). Medical disorders in the schizophrenic patient. International Journal of Psychiatry in Medicine, 25, 137-172.
44. Vreeland, B., Minsky, S., Menza, M., Rigassio Radler, D., Roemheld-Hamm, B., & Stern, R. (2003). A program for managing weight gain associated with atypical antipsychotics. Psychiatric Services, 54, 1155-1157.
45. Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D. E., Pashdag, J., et al. (1999). Novel antipsychotics: Comparison of weight gain liabilities. Journal of Clinical Psychiatry, 60, 358-363.
46. World Health Organization. (2002). Obesity: Preventing and managing the global epidemic. Report of o World Health Organization Consultation. Geneva, Switzerland: Author.
47. Ziedonis, D. M., Kosten, T. R., Glazer, W. M., & Frances, R. J. (1994). Nicotine dependence and schizophrenia. Hospital & Community Psychiatry, 45, 204-206.